217 related articles for article (PubMed ID: 25420920)
1. Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?
Seideman C; Canter D; Kim P; Cordon B; Weizer A; Oliva I; Rao J; Inman BA; Posch M; Herr H; Lotan Y
World J Urol; 2015 Sep; 33(9):1309-13. PubMed ID: 25420920
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
Bergman J; Reznichek RC; Rajfer J
BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
[TBL] [Abstract][Full Text] [Related]
3. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
Schlomer BJ; Ho R; Sagalowsky A; Ashfaq R; Lotan Y
J Urol; 2010 Jan; 183(1):62-7. PubMed ID: 19913822
[TBL] [Abstract][Full Text] [Related]
4. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder.
Fritsche HM; Burger M; Dietmaier W; Denzinger S; Bach E; Otto W; Doblinger M; Schwarz S; Buchner H; Hartmann A
Am J Clin Pathol; 2010 Oct; 134(4):597-603. PubMed ID: 20855641
[TBL] [Abstract][Full Text] [Related]
5. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer.
Zellweger T; Benz G; Cathomas G; Mihatsch MJ; Sulser T; Gasser TC; Bubendorf L
Int J Cancer; 2006 Oct; 119(7):1660-5. PubMed ID: 16646074
[TBL] [Abstract][Full Text] [Related]
6. Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.
Kim PH; Sukhu R; Cordon BH; Sfakianos JP; Sjoberg DD; Hakimi AA; Dalbagni G; Lin O; Herr HW
BJU Int; 2014 Sep; 114(3):354-9. PubMed ID: 24128299
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
Lotan Y; Bensalah K; Ruddell T; Shariat SF; Sagalowsky AI; Ashfaq R
J Urol; 2008 Jun; 179(6):2164-9. PubMed ID: 18423745
[TBL] [Abstract][Full Text] [Related]
8. Intermediate-risk urothelial carcinoma: an unresolved problem?
Pycha A; Lodde M; Comploj E; Negri G; Egarter-Vigl E; Vittadello F; Lusuardi L; Palermo S; Mian C
Urology; 2004 Mar; 63(3):472-5. PubMed ID: 15028440
[TBL] [Abstract][Full Text] [Related]
9. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy.
Whitson J; Berry A; Carroll P; Konety B
BJU Int; 2009 Aug; 104(3):336-9. PubMed ID: 19220253
[TBL] [Abstract][Full Text] [Related]
10. UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.
Bubendorf L; Piaton E
Ann Pathol; 2012 Dec; 32(6):e52-6, 438-43. PubMed ID: 23244486
[TBL] [Abstract][Full Text] [Related]
11. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of nondiagnostic molecular changes in urine detected by UroVysion fluorescence in situ hybridization during surveillance for bladder cancer.
Nguyen CT; Litt DB; Dolar SE; Ulchaker JC; Jones JS; Brainard JA
Urology; 2009 Feb; 73(2):347-50. PubMed ID: 19022486
[TBL] [Abstract][Full Text] [Related]
13. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
14. The utility of fluorescence in situ hybridization for diagnosis and surveillance of bladder urothelial carcinoma.
Huang JW; Mu JG; Li YW; Gan XG; Song LJ; Gu BJ; Fu Q; Xu YM; An RH
Urol J; 2014 Nov; 11(6):1974-9. PubMed ID: 25433477
[TBL] [Abstract][Full Text] [Related]
15. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
16. Bladder wash cytology at diagnosis of Ta-T1 bladder cancer is predictive for recurrence and progression.
Jancke G; Rosell J; Chebil G; Jahnson S
Urology; 2012 Sep; 80(3):625-31. PubMed ID: 22925239
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma.
Gayed BA; Seideman C; Lotan Y
J Urol; 2013 Oct; 190(4):1181-6. PubMed ID: 23583531
[TBL] [Abstract][Full Text] [Related]
18. Cytologic and cystoscopic predictors of recurrence and progression in patients with low-grade urothelial carcinoma.
Jackson J; Barkan GA; Kapur U; Wojcik EM
Cancer Cytopathol; 2013 Jul; 121(7):398-402. PubMed ID: 23364860
[TBL] [Abstract][Full Text] [Related]
19. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
20. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer.
Gofrit ON; Zorn KC; Silvestre J; Shalhav AL; Zagaja GP; Msezane LP; Steinberg GD
Urol Oncol; 2008; 26(3):246-9. PubMed ID: 18452813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
